Cardiac Abnormalities in a Predictive Mouse Model of Chagas Disease

Amanda Fortes Francisco1, Giovane R Sousa2, Mhairi Vaughan3

  • 1Department of Infection Biology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

PubMed

Insights

A new mouse model using the Trypanosoma cruzi parasite effectively mimics human Chronic Chagas cardiomyopathy (CCC). This model shows early indicators of heart disease, aiding research into new treatments for this prevalent condition.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Parasitology

Background:

  • Chronic Chagas cardiomyopathy (CCC) is a significant cause of heart disease in endemic regions, stemming from Trypanosoma cruzi infection.
  • Previous studies noted variable cardiac fibrosis in C3H/HeN mice infected with T. cruzi JR strain, similar to human CCC spectrum.
  • The C3H/HeN:JR host:parasite combination was investigated for its potential as an experimental model for CCC.

Purpose of the Study:

  • To evaluate the C3H/HeN:JR host:parasite combination as a model for Chronic Chagas cardiomyopathy (CCC).
  • To identify and correlate electrocardiographic (ECG) markers with cardiac functional abnormalities in T. cruzi-infected mice.

Main Methods:

  • Utilized electrocardiography (ECG) to monitor T. cruzi-infected C3H/HeN mice.
  • Assessed cardiac inflammation and inducible nitric oxide synthase (iNOS) expression.
  • Investigated the role of denervation in the observed pathology.

Main Results:

  • The C3H/HeN:JR model frequently exhibited early CCC indicators, including sinus bradycardia and right bundle branch block.
  • Prolonged PQ, PR, RR, ST, and QT intervals were observed in the acute stage.
  • High cardiac inflammation and enhanced iNOS expression were present in the acute stage; denervation was not implicated.

Conclusions:

  • The C3H/HeN:JR host:parasite combination serves as a viable experimental model for CCC.
  • This model can be used for screening therapeutic compounds targeting cardiac remodeling.
  • It also facilitates examination of antiparasitic drugs for preventing or mitigating CCC development and progression.

Related Concept Videos